Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder

NCT: NCT06572683 · ENROLLING_BY_INVITATION

NCT IDNCT06572683
StatusENROLLING_BY_INVITATION
Start Date2024-02-12
Completion2028-10-31
SponsorUniversity of California, Los Angeles (OTHER)
First posted
Last updated

Brief Summary

The purpose of the study is to develop a more personalized brain stimulation using repetitive transcranial magnetic stimulation or rTMS approach to treat major depressive disorder (MDD). The investigators had previously developed a personalized rTMS treatment by examining the effectiveness of different rTMS frequency from 5 to 18 Hertz (Hz). The optimal treatment frequency is termed resonance frequency and varies across individuals. There has not been a systematic method to identify the best stimulation frequency in an individual-specific way. In this project, the investigators will identify and compare 3 rTMS frequencies, all targeting the brain region called left dorsolateral prefrontal cortex (DLPFC): 1 that engages brain circuit connectivity the most- the investigators call this resonant frequency (RF)-max (RF-max), 1 that is the lowest ranked resonance frequency called RF-min and 1 that is standard of care treatment - rTMS of 10 Hz as a point of comparison. This study is a multi-sites project that will be conducted at UCLA and Butler hospital. This study will enroll 84 participants with MDD over the course of 4.5 years. Participants will undergo a brain imaging scan or magnetic resonance imaging (MRI), 3 electroencephalograms (or EEG, a measurement of electrical activity of the brain), to identify rTMS resonance frequencies (RFs), 3 sessions of different resonant frequencies of rTMS in combination with EEG, totaling up to 7 in person visits. Participation will take up to 4 weeks.

Frequently Asked Questions

What is Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder?

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder is a clinical trial registered under NCT06572683. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT06572683?

The current status of NCT06572683 (Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder) is: ENROLLING_BY_INVITATION.

When did Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder start?

Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder started on 2024-02-12.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑